The PubMed entry catalogs a clinical trial analysis titled "Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial." The item is indexed in J Clin Oncol (2026 Oct 20;44[30]:2941-2952), DOI 10.1200/JCO-26-00769, and carries PubMed ID 42715505. Ajay Subramanian is listed first among a multi-institutional author group; affiliations include Stanford University, Mayo Clinic, Duke Cancer Institute, University of Toronto, and several international radiation oncology centers. The PubMed record classifies the item as a Clinical Trial and confirms electronic publication on Sep 9, 2026, ahead of the October issue.
The title explicitly names circulating tumor DNA as the analytic tool and references pembrolizumab delivered alongside radiotherapy in patients with localized sarcomas. Those key terms anchor the likely clinical focus: biomarker-driven monitoring during combined-modality therapy.
The index page supplies standard bibliographic metadata: full author list, institutional affiliations, journal citation, DOI, and PMID. The presence of a trial acronym, SU2C-SARC032, indicates the work was conducted within an organized trial framework and reported to a peer-reviewed oncology journal. The title indicates two linked objectives: predicting outcomes using personalized ctDNA analysis and tracking treatment response during radiotherapy plus pembrolizumab. The record therefore signals that ctDNA was applied both as a prognostic and as a dynamic response biomarker in the trial context.
Investigators reported the submission and publication details on PubMed; the display confirms article provenance and authorship across several academic centers. That provenance supports the expectation of standard clinical trial reporting practices in the full manuscript (trial design, endpoints, methods), but the PubMed listing itself does not provide those primary data.
The PubMed page captured here does not include the abstract text or the manuscript body. As a result, the record does not report any of the following trial-essential items: sample size or enrollment numbers; ctDNA assay design and analytic validation (for example, targeted mutations, limit of detection, or bioinformatics pipeline); blood sampling timepoints relative to radiotherapy and immunotherapy; radiotherapy dose, fractionation, or target volumes; pembrolizumab dose and schedule; primary and secondary endpoints (progression-free survival, local control, pathologic response, overall survival, or ctDNA-based endpoints); statistical methods, effect estimates, confidence intervals, or P values; adverse event rates or safety signals; or subgroup analyses by histology or stage.
Because those elements are absent from the displayed record, no quantitative findings, predictive performance metrics (sensitivity, specificity, negative predictive value), or conclusions about clinical validity or utility can be extracted from this PubMed entry alone. The PubMed listing documents publication metadata only — it does not substitute for the full article when evaluating clinical evidence.
From the title we can infer the trial addresses an unmet need in sarcoma care: noninvasive biomarkers to anticipate outcomes and to monitor response during combined radiotherapy and immune checkpoint blockade. The inclusion of pembrolizumab suggests an immune-oncology component. The use of personalized ctDNA assays implies mutation-informed or patient-specific molecular tracking rather than a fixed-panel screening approach. The SU2C (Stand Up To Cancer) affiliation embedded in the acronym suggests collaborative funding or trial sponsorship, although PubMed’s display does not expand on funding or trial governance.
These contextual inferences are consistent with contemporary approaches in solid tumors where ctDNA is explored for minimal residual disease detection and early response assessment. Still, such logical connections remain inferences; the PubMed entry does not provide confirmation or numeric evidence of efficacy, assay performance, or clinical impact.
Clinicians and researchers interested in the trial’s methods and outcomes should access the full J Clin Oncol article via the DOI 10.1200/JCO-26-00769 or through institutional journal access. The PubMed record confirms the citation and identifiers needed to retrieve the manuscript. Review priorities once the full text is obtained: confirm ctDNA assay platform and analytical validation, review sampling schedule relative to therapy milestones, examine defined primary and secondary endpoints, evaluate reported effect sizes and statistical robustness, and inspect safety data for combined radiotherapy and checkpoint inhibition.
If the full manuscript is not accessible, contact corresponding authors or institutional trial sites listed in the PubMed entry for protocol documents or supplementary materials. Trial registries (clinicaltrials.gov or equivalent) may also host protocol summaries and pre-specified endpoints for SU2C-SARC032; the PubMed entry does not include a registry identifier on the displayed page.
The PubMed listing provides robust bibliographic details but does not present trial data or methods on the captured page. Therefore, critical questions remain unanswered in this source: What were the primary endpoints and their numerical outcomes? How was ctDNA personalized and validated? What were the enrollment criteria, sample size, and statistical thresholds? What safety signals emerged from the radiotherapy plus pembrolizumab regimen? The PubMed record does not provide answers to these items.
Readers should obtain and scrutinize the full J Clin Oncol manuscript to evaluate clinical applicability. Until the primary paper and any supplementary materials are reviewed, any statements about efficacy, predictive accuracy, or clinical adoption of ctDNA monitoring in this trial would be speculative and are not supported by the PubMed entry alone.